SOURCE: The Bedford Report

The Bedford Report

June 23, 2011 08:16 ET

Investors Hopeful for Blockbusters From Rexahn and RXi Pharmaceuticals

The Bedford Report Provides Stock Research on RXi Pharmaceuticals & Rexahn Pharmaceuticals

NEW YORK, NY--(Marketwire - Jun 23, 2011) - Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation as has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on RXi Pharmaceuticals Corporation (NASDAQ: RXII) and Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN). Access to the full company reports can be found at:

Cancer medication is also an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive post-marketing studies to confirm clinical benefit.

The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Earlier this year the company said that it has been granted a European patent for its anti-cancer compounds.

RXi Pharmaceuticals' lead product candidates include NeuVax, which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients. RXi acquired NeuVax from privately held Apthera earlier this year. Apthera completed Phase II trials of NeuVax with positive efficacy data and favorable safety profile.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information